KDIGO 2026 Anemia in CKD Guideline: ESA First, Proactive IV Iron in Hemodialysis
The first KDIGO anemia update since 2012 splits iron thresholds by dialysis status, positions ESAs ahead of HIF-PHIs, and moves transfusion decisions to symptoms with transplant allosensitization in mind.
📅 Journal publication: Sep 15, 2026·Last updated: Nov 5, 2026
Updated guidelines prioritize personalized anemia management in chronic kidney disease.
Anemia is a prevalent complication in chronic kidney disease (CKD) affecting patient outcomes and quality of life. The guideline updates include preference for intravenous iron in hemodialysis, individualized hemoglobin thresholds, and choosing erythropoiesis-stimulating agents over hypoxia-inducible factor-prolyl hydroxylase inhibitors. Reinforces dosing strategies focused on individual patient needs for anemia management in CKD, emphasizing safety and efficacy of therapies. Revised guidelines optimize anemia treatment in CKD with tailored iron and erythropoiesis-stimulating agent use.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Hedayati SS, Babitt JL, Berns JS, Bozkurt B, Cheung RS, Cuevas Y, Effa EE, Eisenga MF, Fishbane S, Ginzburg YZ, Haase VH, Kim S, Moura-Neto JA, Rossignol P, Sahay M, Tanaka T, Wang AY, Wheeler DC, Robinson KA, Wilson LM, Wilson RF, King JM, Earley A, Akl EA, Tonelli M, Nagler EV
Citation:Hedayati SS, Babitt JL, Berns JS, et al. Evaluation and Management of Anemia in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2026 Clinical Practice Guideline. Annals of internal medicine. 2026. doi:10.7326/ANNALS-26-02326